A U.S. appeals court in Texas has ruled in favor of Pozen in a patent infringement case involving the Chapel Hill company's Treximet migraine drug.
The ruling by the U.S. District Court for the Eastern District of Texas reaffirmed a lower court's ruling that generic versions of the drug would infringe on several patents.
Pozen had sued to prevent Par Pharmaceutical and Dr. Reddy's Laboratories from manufacturing the drug.
GlaxoSmithKline licensed the rights to Treximet from Pozen in 2003 and has marketed the drug since its approval by federal regulators in 2008.
Most of Pozen's revenue comes from Treximet and its Vimovo arthritis pain reliever, sold by AstraZeneca.
Pozen reported a net loss of $8.4 million, or 28 cents per share, in the first quarter, compared with $5.7 million, or 19 cents per share, during the same period a year ago.
The company attributed the larger loss to lower royalty payments from Treximet.
Pozen is also developing an easier-to-stomach aspirin that combines aspirin and a gastrointestinal medicine. The drug is aimed at helping to prevent heart disease and stroke in patients who are susceptible to aspirin-induced ulcers.